Certain A Shares of Beijing Balance Medical Technology Co.,Ltd. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. These A Shares will be under lockup for 2198 days starting from 3-DEC-2019 to 9-DEC-2025.
Details:
The company's controlling shareholders, Jin Lei and Li Fengling, Shareholder Baiao Furen Investments Co., Ltd., Baiao Enterprise Management Co., Ltd and Jin Sen committed that within 36 months since the date of listing of the present shares, there will be no transfers nor entrustment of shares to any third party nor repurchase by the Company. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect, held by the present parties. In the event of a resignation before the expiry of the term of office, the above-mentioned undertaking will continue to be maintained for six months
Jin Lei, Li Liyan, Cheng Qi, Wang Donghui, Zhang Yanfang and Mu Hong, respectively, who are directors, supervisors and senior managers of the company, commit not to within 12 months since the date of listing of the present shares, there will not be no transfers nor entrustment of shares to any third party nor repurchase by the Company. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. If there is any case of dividends, bonus shares, capitalization of capital reserve and other similar cases, issue price will be adjusted according to ex-dividend and ex-interests. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect, held by the present parties. In the event of a resignation before the expiry of the term of office, the above-mentioned undertaking will continue to be maintained for six months.
Beijing Balance Medical Technology Co Ltd is a China-based company mainly engaged in the research and development (R&D) and production of animal derived interventional medical devices. The Company's products cover three fields: heart valve replacement and repair, implantable interventional therapy for congenital heart disease and surgical soft tissue repair. The heart valve replacement and repair products include artificial biological heart valves and valve forming rings. The implantable interventional therapy products for congenital heart disease include cardiothoracic surgical biological patch, outflow tract single valve patch, atrial defect occlude and others. The surgical soft tissue repair products include neurosurgical biological patch, biological hernia patch and others. The Company operates its businesses mainly in the domestic market.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.